The FDA have moved to expedite the approval of a new therapy for forms of ovarian cancer that currently lack effective treatment options.
Patients with newly diagnosed stage IIIb-IV ovarian cancer are typically treated with debulking surgery and combination chemotherapy, although this approach is associated with high relapse and low survival rates. PARP inhibitors and checkpoint inhibitor therapy have also been trialled in these patients with little success.
But a recent clinical trial has investigated the potential benefits of an immunotherapy-based approach involving gemogenovatucel-T. The latest findings from the trial have been published in JCO Precision Oncology and suggest the drug improves survival relative to placebo .
“Gemogenovatucel-T is a DNA-engineered triple function immunotherapy using autologous tumour cells as a source of the full matrix of a patient’s tumour-related clonal signals,” the researchers wrote.
